Week Ending December 27, 2021

High cost of treatment, lack of drugs bane of Hepatitis patients
“More than half of people with Hepatitis B in the country do not receive treatment due to the high cost of drugs and their non-availability at public health facilities.”

New research could open up a new era of antiviral therapies
“Researchers have proposed a novel antiviral strategy which repurposes and misdirects how a virus assembles.”

People with serious mental illness ‘priority group’ for HCV screening
“Individuals with serious mental illness had high hepatitis C virus prevalence, according to results of a systematic review and meta-analysis published in Journal of Clinical Psychiatry.”

You Know of Hepatitis A, B and C. Here’s HUC: Hepatitis of Unknown Cause
“Most everyone has heard of hepatitis A, B and C viruses (HAV, HBV and HCV). But sometimes the cause of the hepatitis remains mysterious. Health experts refer to such cases as hepatitis of unknown cause (HUC).”

‘Almost like you’re a detective’: Clinicians explain how they got Hooked on ID
“For years, we have been asking you to tell us why you chose a career in infectious diseases, a specialty whose importance has hardly been more apparent. We continue to be captivated by the stories you tell.”

5 Fruits that will help you cleanse the liver, know them and add them to your daily diet
“The liver is one of the largest organs within body, being also one of the most important that we have. This is in charge of helping the body digest the food, store energy and eliminate toxins, precisely for this reason, you must take care of it too much and, much of it, also goes with the part of having a healthy and balanced diet.”

HCC Prevention Should Be Targeted to Patients With Moderate Fibrosis
“The majority of cases of hepatocellular carcinoma (HCC) unrelated to hepatitis or cirrhosis occur in individuals with an intermediate degree of fibrosis. Efforts to tackle risk factors, such as obesity, diabetes, unhealthy alcohol use, and smoking, might be best targeted to those with an intermediate level of hepatic fibrosis as indicated by FIB-4.”